Who Paid My Doc
Thomas Marron
Medical Oncology New York, NY Medical Doctor
NPI 1821363029 CMS profile 1389322
10 E 102Nd St, New York, NY 10029
General payments
$155,325
Research payments
$50,991
Ownership & investment interest
$0
Research they led as principal investigator
$7,901,487
Through program year 2025, Thomas Marron of New York, NY is reported in the CMS Open Payments database as having received $155,325 across 182 general payments and $50,991 in research payments paid to them. Separately, studies naming them as principal investigator received $7,901,487 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $22,844 | 31 | |
| 2025 | Research | $3,109 | 5 | |
| 2024 | General | $62,025 | 50 | |
| 2024 | Research | $3,375 | 2 | |
| 2023 | General | $33,322 | 43 | |
| 2023 | Research | $581 | 5 | |
| 2022 | General | $7,767 | 13 | |
| 2022 | Research | $891 | 3 | |
| 2021 | General | $201 | 2 | |
| 2021 | Research | $43,035 | 10 | |
| 2020 | General | $14,767 | 9 | |
| 2019 | General | $14,399 | 34 |
Beside peers
- Thomas Marron
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Thomas Marron were reported at $22,844. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Thomas Marron | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $14,399 | $968 | $140–$6,658 | $163 |
| 2020 | $14,767 | $747 | $102–$5,891 | $114 |
| 2021 | $201 | $430 | $50–$4,098 | $132 |
| 2022 | $7,767 | $812 | $127–$4,907 | $149 |
| 2023 | $33,322 | $957 | $144–$5,248 | $160 |
| 2024 | $62,025 | $1,042 | $149–$5,650 | $164 |
| 2025 | $22,844 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
125
Drug cost
$449,593
Branded share of claims
60.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | Brand | 27 | $448,303 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 22 | $650 | |
| Ondansetron Odt Ondansetron | Brand | 27 | $302 | |
| Mirtazapine | Generic | 11 | $184 | |
| Prochlorperazine Maleate | Generic | 16 | $126 | |
| Famotidine | Generic | 22 | $28 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$25,663
Medicare patients
69
Services billed
213
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Cancer | 70% | |
| Ischemic heart disease | 43% | |
| Diabetes | 41% | |
| Arthritis | 39% | |
| COPD | 29% | |
| Chronic kidney disease | 28% | |
| Depression | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
4 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| LIBTAYO |
|
$5,584 | — | — |
| Udenyca |
|
$148 | — | — |
| KRAZATI |
|
$105 | — | — |
| ZEPZELCA |
|
$27 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
207 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Medical Oncology in New York
Related records
Medical Oncology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.